GALE Share Price

Open 0.63 Change Price %
High 0.72 1 Day 0.05 7.81
Low 0.62 1 Week -0.06 -8.00
Close 0.69 1 Month -1.15 -62.50
Volume 1854844 1 Year -0.14 -16.87
52 Week High 4.75
52 Week Low 0.16
GALE Important Levels
Resistance 2 0.78
Resistance 1 0.74
Pivot 0.68
Support 1 0.64
Support 2 0.60
NASDAQ USA Most Active Stocks
DRYS 2.24 -4.68%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
ASTI 0.00 0.00%
More..
NASDAQ USA Top Gainers Stocks
MYRX 0.10 100.00%
LOCM 0.09 50.00%
CEMP 4.05 28.57%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SKBI 0.10 25.00%
IPCI 2.55 18.60%
QKLS 0.15 15.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
GMETP 0.70 -59.54%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
EDMC 0.01 -50.00%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Galena Biopharma, Inc. (NASDAQ: GALE)

GALE Technical Analysis 5
As on 24th Feb 2017 GALE Share Price closed @ 0.69 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.23 & Strong Sell for SHORT-TERM with Stoploss of 1.67 we also expect STOCK to react on Following IMPORTANT LEVELS.
GALE Target for February
1st Target up-side 1.96
2nd Target up-side 2.17
3rd Target up-side 2.38
1st Target down-side 1.34
2nd Target down-side 1.13
3rd Target down-side 0.92
GALE Other Details
Segment EQ
Market Capital 139060160.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.galenabiopharma.com
GALE Address
GALE
4640 SW Macadam Avenue
Suite 270
Portland, OR 97239
United States
Phone: 855-855-4253
Interactive Technical Analysis Chart Galena Biopharma, Inc. ( GALE NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Galena Biopharma, Inc.
GALE Business Profile
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). In January 2014, Galena Biopharma Inc acquired Mills Pharmaceuticals, which has the worldwide rights to GALE-401 (Anagrelide CR), a patented, controlled release formulation of anagrelide.